Balanced news tone
News Sentiment
CELC sentiment intelligence
Celcuity LLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
74/100 classification confidence.
directly relevant articles
high-authority source matches
-0.3% over one week, +21.5% over four weeks, trend inactive, and materially above fair value.
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Price to earnings forward of Celcuity Inc. – NASDAQ:CELC
This article provides access to the "Price to earnings forward" financial metric for Celcuity Inc. (NASDAQ: CELC) on the TradingView platform. It appears to be a stub or a data point within a larger financial analysis tool, showcasing the company's ticker and market. The content
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 09:41
- Source
- TradingView
Price to sales forward of Celcuity Inc. – DUS:7VR
This article provides the "Price to sales forward" metric for Celcuity Inc. (DUS:7VR) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The page also offers overview information, financials, news, community, techn
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 19:40
- Source
- TradingView
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 2000 Value Benchmark
Celcuity Inc. (NasdaqCM: CELC) has been dropped from the Russell 2000 Value Benchmark, as well as the Russell Microcap Value Benchmark Index, Russell 3000E Growth Benchmark, Russell Microcap Index, and Russell 3000E Index. The company is a clinical-stage biotechnology firm develo
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 29 Jun 2026 15:40
- Source
- www.marketscreener.com
Enterprise value to revenue forward of Celcuity Inc. – NASDAQ:CELC
This article focuses on the enterprise value to revenue forward metric for Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data point presented within a TradingView context, indicating no trades and providing an overview of the company's financial information. The cont
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 23:39
- Source
- TradingView
Enterprise value to EBITDA forward of Celcuity Inc. – MUN:7VR
The article displays the enterprise value to EBITDA forward for Celcuity Inc. (MUN:7VR) on the Munich Stock Exchange. It focuses solely on this financial metric, indicating that the market was closed with no trades at the time of viewing.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 18:39
- Source
- TradingView
Enterprise value to revenue forward of Celcuity Inc. – MUN:7VR
This article provides financial information for Celcuity Inc. (MUN:7VR) listed on the Munich Stock Exchange, specifically focusing on its enterprise value to forward revenue. It appears to be a financial data snippet from a larger platform, offering an overview of the company's f
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 18:10
- Source
- TradingView
Enterprise value to EBIT forward of Celcuity Inc. – NASDAQ:CELC
This article focuses on the enterprise value to EBIT forward of Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data page from TradingView, displaying stock information and financial metrics for the company. The content primarily highlights the "Enterprise value to EBI
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 12:10
- Source
- TradingView
Price to book forward of Celcuity Inc. – MUN:7VR
This article presents the "Price to book forward" financial metric for Celcuity Inc. (MUN:7VR), indicating its value and change over a period. It highlights that the information is 'Made by humans' and uses market data from ICE Data Services and reference data from FactSet.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 04:09
- Source
- TradingView
Celcuity Inc. Actuals & Estimates (HAM:7VR)
This article provides an overview of Celcuity Inc. (7VR) stock performance, analyst estimates, and financial data on the Hamburg Stock Exchange. It includes details on the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 00:09
- Source
- TradingView
A2JAAX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Celcuity Inc. (A2JAAX) stock, including its current price, analyst ratings, and future price predictions. It details the company's financials, such as EPS, revenue, market capitalization, and upcoming earnings dates. The article also addresses
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:41
- Source
- TradingView
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 19:11
- Source
- Simply Wall St.
Celcuity Prices $500 Million Convertible Notes Due 2032
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 12:12
- Source
- MT Newswires
Why is Celcuity stock sliding today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Investing.com
Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)
- Tone
- Negative 38/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Market source
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Celcuity expands phase 3 breast cancer trial design
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Investing.com
Celcuity earnings up next as FDA approval decision looms
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Investing.com
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Market source
Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Apr 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView